Role of CTLA4 and PSTAT3 Immunostaining in Prognosis and Treatment of the Colorectal Carcinoma

Overview

Journal Iran J Pathol

Date 2024 Jun 12

PMID 38864078

Authors

Dina Mohamed Allam

Hend Kasem

Amira Hegazy

Shereen F Mahmoud

Affiliations

Soon will be listed here.

Abstract

Background & Objective: Colorectal carcinoma (CRC) is the third leading cause of cancer-caused death worldwide and constitutes about 6.48% of all malignancies in Egypt. Studying the molecular profile of CRC is essential for developing targeted therapies. STAT3 and CTLA4 expression are considered as molecular abnormalities involved in the CRC progression and chemo-resistance. Therefore, they could be used as potential therapeutic targets. This study aimed to evaluate pSTAT3 and CTLA4 expression levels and their possible roles as prognostic and predictive biomarkers in CRC using immunohistochemistry (IHC).

Methods: This retrospective study included 113 CRC patients. Tissue microarrays were constructed, followed by pSTAT3 and CTLA4 antibodies immunostaining. Their expression was assessed and compared with the clinicopathological parameters and survival data.

Results: Both pSTAT3 and CTLA4 overexpression were significantly associated with poor prognostic parameters, such as the presence of distant metastasis (=0.02 & 0.03), high grade (<0.001 & 0.03), high mitotic count (<0.001 & 0.03), high tumor budding group (=0.008 & 0.04), infiltrating tumor border (<0.001 & 0.007) respectively, and advanced pathological stage with pSTAT3 (=0.02). A significant association was found between overexpression of both markers and short overall survival. Correlations between the H-score of pSTAT3 and CTLA4 in CRC showed a significant positive correlation (<0.001).

Conclusion: STAT3 and CTLA4 positivity may be linked to the development and progression of the CRC, and they may provide potential prognostic indicators and therapeutic targets for CRC patients.

References

Derakhshani A, Hashemzadeh S, Asadzadeh Z, Shadbad M, Rasibonab F, Safarpour H . Cytotoxic T-Lymphocyte Antigen-4 in Colorectal Cancer: Another Therapeutic Side of Capecitabine. Cancers (Basel). 2021; 13(10). PMC: 8155910. DOI: 10.3390/cancers13102414. View

Shi S, Ma H, Zhang Z . Clinicopathological and prognostic value of STAT3/p-STAT3 in cervical cancer: A meta and bioinformatics analysis. Pathol Res Pract. 2021; 227:153624. DOI: 10.1016/j.prp.2021.153624. View

Song L, Wang Y, Zhen Y, Li D, He X, Yang H . Piperine inhibits colorectal cancer migration and invasion by regulating STAT3/Snail-mediated epithelial-mesenchymal transition. Biotechnol Lett. 2020; 42(10):2049-2058. DOI: 10.1007/s10529-020-02923-z. View

Contardi E, Palmisano G, Tazzari P, Martelli A, Fala F, Fabbi M . CTLA-4 is constitutively expressed on tumor cells and can trigger apoptosis upon ligand interaction. Int J Cancer. 2005; 117(4):538-50. DOI: 10.1002/ijc.21155. View

Kusaba T, Nakayama T, Yamazumi K, Yakata Y, Yoshizaki A, Inoue K . Activation of STAT3 is a marker of poor prognosis in human colorectal cancer. Oncol Rep. 2006; 15(6):1445-51. View

Lorente D, Trilla E, Meseguer A, Arevalo J, Nemours S, Planas J . The role of STAT3 protein as a prognostic factor in the clear cell renal carcinoma. Systematic review. Actas Urol Esp (Engl Ed). 2018; 43(3):118-123. DOI: 10.1016/j.acuro.2018.08.003. View

Santoni G, Amantini C, Morelli M, Tomassoni D, Santoni M, Marinelli O . High CTLA-4 expression correlates with poor prognosis in thymoma patients. Oncotarget. 2018; 9(24):16665-16677. PMC: 5908277. DOI: 10.18632/oncotarget.24645. View

Xiong H, Zhang Z, Tian X, Sun D, Liang Q, Zhang Y . Inhibition of JAK1, 2/STAT3 signaling induces apoptosis, cell cycle arrest, and reduces tumor cell invasion in colorectal cancer cells. Neoplasia. 2008; 10(3):287-97. PMC: 2259457. DOI: 10.1593/neo.07971. View

Lebwohl D, Kay A, Berg W, Baladi J, Zheng J . Progression-free survival: gaining on overall survival as a gold standard and accelerating drug development. Cancer J. 2009; 15(5):386-94. DOI: 10.1097/PPO.0b013e3181b9c5ec. View

10.

Corvinus F, Orth C, Moriggl R, Tsareva S, Wagner S, Pfitzner E . Persistent STAT3 activation in colon cancer is associated with enhanced cell proliferation and tumor growth. Neoplasia. 2005; 7(6):545-55. PMC: 1501283. DOI: 10.1593/neo.04571. View

11.

Zhang X, Pan K, Weng D, Chen C, Wang Q, Zhao J . Cytotoxic T lymphocyte antigen-4 expression in esophageal carcinoma: implications for prognosis. Oncotarget. 2016; 7(18):26670-9. PMC: 5042006. DOI: 10.18632/oncotarget.8476. View

12.

Kilickap S, Demirci U, Karadurmus N, Dogan M, Akinci B, Sendur M . Endpoints in oncology clinical trials. J BUON. 2019; 23(7):1-6. View

13.

Nagtegaal I, Odze R, Klimstra D, Paradis V, Rugge M, Schirmacher P . The 2019 WHO classification of tumours of the digestive system. Histopathology. 2019; 76(2):182-188. PMC: 7003895. DOI: 10.1111/his.13975. View

14.

Song D, Guo M, Xu S, Song X, Bai B, Li Z . HSP90-dependent PUS7 overexpression facilitates the metastasis of colorectal cancer cells by regulating LASP1 abundance. J Exp Clin Cancer Res. 2021; 40(1):170. PMC: 8120699. DOI: 10.1186/s13046-021-01951-5. View

15.

Eisenhauer E, Therasse P, Bogaerts J, Schwartz L, Sargent D, Ford R . New response evaluation criteria in solid tumours: revised RECIST guideline (version 1.1). Eur J Cancer. 2008; 45(2):228-47. DOI: 10.1016/j.ejca.2008.10.026. View

16.

Topalian S, Drake C, Pardoll D . Immune checkpoint blockade: a common denominator approach to cancer therapy. Cancer Cell. 2015; 27(4):450-61. PMC: 4400238. DOI: 10.1016/j.ccell.2015.03.001. View

17.

Morikawa T, Baba Y, Yamauchi M, Kuchiba A, Nosho K, Shima K . STAT3 expression, molecular features, inflammation patterns, and prognosis in a database of 724 colorectal cancers. Clin Cancer Res. 2011; 17(6):1452-62. PMC: 3077111. DOI: 10.1158/1078-0432.CCR-10-2694. View

18.

Li M, Bi X, Huang Z, Zhao J, Han Y, Li Z . Prognostic Role of Phospho-STAT3 in Patients with Cancers of the Digestive System: A Systematic Review and Meta-Analysis. PLoS One. 2015; 10(5):e0127356. PMC: 4449159. DOI: 10.1371/journal.pone.0127356. View

19.

Goto M, Chamoto K, Higuchi K, Yamashita S, Noda K, Iino T . Analytical performance of a new automated chemiluminescent magnetic immunoassays for soluble PD-1, PD-L1, and CTLA-4 in human plasma. Sci Rep. 2019; 9(1):10144. PMC: 6626008. DOI: 10.1038/s41598-019-46548-3. View

20.

Zhang H, Dutta P, Liu J, Sabri N, Song Y, Li W . Tumour cell-intrinsic CTLA4 regulates PD-L1 expression in non-small cell lung cancer. J Cell Mol Med. 2018; 23(1):535-542. PMC: 6307812. DOI: 10.1111/jcmm.13956. View